Tecovirimat Resistance in Mpox Patients, United States, 2022-2023
Tecovirimat Resistance in Mpox Patients, United States, 2022-2023
About this item
Full title
Author / Creator
Smith, Todd G , Gigante, Crystal M , Wynn, Nhien T , Matheny, Audrey , Davidson, Whitni , Yang, Yong , Condori, Rene Edgar , O'Connell, Kyle , Kovar, Lynsey , Williams, Tracie L , Yu, Yon C , Petersen, Brett W , Baird, Nicolle , Lowe, David , Li, Yu , Satheshkumar, Panayampalli S and Hutson, Christina L
Publisher
United States: U.S. National Center for Infectious Diseases
Journal title
Language
English
Formats
Publication information
Publisher
United States: U.S. National Center for Infectious Diseases
Subjects
More information
Scope and Contents
Contents
During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, an...
Alternative Titles
Full title
Tecovirimat Resistance in Mpox Patients, United States, 2022-2023
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9a123816218646aabeb63e8826093b2a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9a123816218646aabeb63e8826093b2a
Other Identifiers
ISSN
1080-6040
E-ISSN
1080-6059
DOI
10.3201/eid2912.231146
